Lundbeck

179 articles with Lundbeck

• 

  Alzheimer’s Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

  9/23/2019

  50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.

• Lundbeck selects Discngine’s 3decision® platform to leverage complex protein-ligand 3D structure data in the discovery of new treatments for brain diseases

  9/4/2019

  Discngine announces that Lundbeck has selected its proprietary 3decision® collaborative platform to manage the pharma company’s structural knowledge related to protein and ligand 3D structures.

• P1vital announces launch of the Reward Task Optimisation Consortium - RTOC

  7/22/2019

  Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium.

• Lundbeck Tops Corporate Reputation Rankings for Fourth Consecutive Year

  5/31/2019

  Annual survey finds Lundbeck US is first among leading pharmaceutical companies in the eyes of patient groups.

• 

  Jazz Pharma, Lundbeck and Alexion Pay $122 Million to Settle Kickback Allegations

  4/4/2019

  The government charged the three companies with using charitable foundations they financially supported to finance copays of Medicare and Medicaid patients, which is a violation of law.

• Numerate and Lundbeck Partner to Apply AI Drug Discovery to Unlock Challenges of Neuroscience Research

  1/7/2019

  Collaboration sets out to identify potential treatment candidates for disorders of the central nervous system including depression, psychosis, seizure and neurodegenerative disorders.

• Survey Findings Highlight the Burden of Neurogenic Orthostatic Hypotension (nOH) on Patients and Care Partners

  9/24/2018

  Symptoms of nOH may affect approximately one in five people with Parkinson’s Disease

• 

  CDC: 14 Million Americans Will Have Alzheimer’s by 2060

  9/21/2018

  Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the firs...

• Catalyst Pharmaceuticals Expands Commercial Leadership Team

  8/6/2018

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.

• Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease

  5/23/2018

  Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.

• 

  Does Novartis’ Acquisition of AveXis Spell Trouble for Biogen?

  4/11/2018

  Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
• 

  Another One Bites the Dust: vTv Therapeutics’ Alzheimer’s Drug Fails in Phase III Trial

  4/10/2018

  Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.

• Study Evaluates Refractory Epilepsy Screening Tool for LGS (REST-LGS)

  12/4/2017

  Lundbeck today presented data at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. that demonstrates that the Refractory Epilepsy Screening Tool for LGS (REST-LGS) may help healthcare professionals identify patients who may benefit from further clinical evaluation for Lennox-Gastaut syndrome (LGS).

• Otsuka Pharma And Lundbeck Announce Initiation Of Two Phase III Trials Of Brexpiprazole In Patients With Bipolar I Disorder

  10/12/2017

• Otsuka Pharmaceutical Development & Commercialization, Inc. And Lundbeck To Showcase Safety And Efficacy Data In Treatments For Challenging Mental Health Conditions

  9/13/2017

• Lundbeck Reports 13% Revenue Growth And A Doubling Of EBIT In First Half Of 2017

  8/9/2017

• Lundbeck Collaborates On Large First-Of-Its Kind Study Of Links Between Genetics And Psychiatric Disorders

  8/2/2017

• Otsuka Pharma And Lundbeck Announce Results Of Brexpiprazole On Symptoms Of Agitation Related To Alzheimer’s-Type Dementia

  5/2/2017

• Mixed Data For Alzheimer’s-Type Dementia Drug Leave Lundbeck, Otsuka Pharma Investors Unsettled

  5/2/2017

• Health Canada Approves Otsuka Pharma And Lundbeck's REXULTI (Brexpiprazole) As A Treatment For Schizophrenia In Adults

  2/20/2017